# US 2021/0267986 A1 · Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0267986 A1
- Document ID: US20210267986A1
- Status: Published application
- Kind: A1
- Application number: 17/315,011
- Filed: 2021-05-07
- Published: 2021-09-02
- Earliest claimed: 2018-11-09
- Assignees: G1 Therapeutics, Inc.
- Applicants: G1 Therapeutics, Inc.
- Inventors: Jessica A. Sorrentino; Patrick Joseph Roberts; Jay Copeland Strum
- Web page: https://patentgrep.com/patent/US20210267986A1

## CPC

- A61K 31/527: spiro-condensed
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/04: specific for metastasis
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods and compositions for treating cancers with a combination of eribulin and a selective CDK4/6 inhibitor, wherein the selective CDK4/6 inhibitor reduces eribulin's effects on myelosuppression and/or myeloablation without reducing the efficacy of eribulin therapy.

## Claims

### Claim 1

A method for treating cancer in a human comprising:
administrating to the human an effective amount of a selective CDK4/6 inhibitor; and
administering to the human an effective amount of eribulin, or a pharmaceutically acceptable salt thereof;
wherein the CDK4/6 inhibitor is administered 4 hours or less prior to administration of eribulin;
and wherein the selective CDK4/6 inhibitor is
or or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable salt of eribulin is eribulin mesylate.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cancer is selected from the group consisting of breast cancer, unresectable/metastatic liposarcoma, non-small cell lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, bladder cancer, osteosarcoma, leiomyosarcoma, ovarian cancer, cervical cancer, colon cancer, head and neck cancer, sarcoma, relapsed/refractory rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, Ewing sarcoma, angiosarcoma, epithelioid hemangioendothelioma, and urothelial cell cancer.

### Claim 4 (depends on 3)

The method of claim 3, wherein the breast cancer is selected from the group consisting of metastatic breast cancer, triple-negative breast cancer, triple-positive breast cancer, HER2-negative breast cancer, HER2-positive breast cancer, estrogen receptor-positive breast cancer, estrogen receptor-negative breast cancer, progesterone receptor-positive breast cancer, progesterone receptor negative breast cancer, ductal carcinoma in situ (OCiS), invasive ductal carcinoma, invasive lobular carcinoma, inflammatory breast cancer, Paget disease of the nipple, phyllodes tumor, and a hormone responsive cancer.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cancer is a CDK4/6-replication dependent cancer.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cancer is a CDK4/6 replication independent cancer.

### Claim 7 (depends on 1)

The method of claim 1, wherein the human is administered the CDK4/6 inhibitor about 30 minutes or less prior to administration of eribulin, or its pharmaceutically acceptable salt.

### Claim 8 (depends on 1)

The method of claim 1, wherein the eribulin is administered on days 1 and 8 of a 21-day chemotherapeutic cycle, and the CDK4/6 inhibitor is administered on days 1 and 8 of a 21-day chemotherapeutic cycle.

### Claim 9 (depends on 1)

The method of claim 1, wherein the eribulin is administered on days 1, 8, and 15 of a 28-day chemotherapeutic cycle, and the CDK4/6 inhibitor is administered on days 1, 8, and 15 of a 28-day chemotherapeutic cycle.

### Claim 10 (depends on 4)

The method of claim 4, further comprising the administration of an anti-hormonal agent, wherein the anti-hormonal agent is selected from the group consisting of a SERM (selective estrogen receptor modulator), a SERD (selective estrogen receptor degrader), a complete estrogen receptor degrader, or another form of partial or complete estrogen antagonist, selective androgen receptor modulator, a selective androgen receptor degrader, a complete androgen receptor degrader, and another form of partial or complete androgen antagonist.

### Claim 11 (depends on 10)

The method of claim 10, wherein the anti-hormonal agent is selected from the group consisting of fulvestrant, tamoxifen, anastrozole, letrozole, exemestane, goserelin, and leuprolide.

### Claim 12

A method for reducing myelosuppression in a human receiving eribulin for the treatment of a cancer comprising:
administrating to the human an effective amount of a selective CDK4/6 inhibitor; and
administering to the human an effective amount of eribulin, or a pharmaceutically acceptable salt thereof;
wherein the CDK4/6 inhibitor is administered 4 hours or less prior to administration of eribulin;
and wherein the selective CDK4/6 inhibitor is
or or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the pharmaceutically acceptable salt of eribulin is eribulin mesylate.

### Claim 14 (depends on 12)

The method of claim 12, wherein the cancer is selected from the group consisting of breast cancer, unresectable/metastatic liposarcoma, non-small cell lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, bladder cancer, osteosarcoma, leiomyosarcoma, ovarian cancer, cervical cancer, colon cancer, head and neck cancer, sarcoma, relapsed/refractory rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, Ewing sarcoma, angiosarcoma, epithelioid hemangioendothelioma, and urothelial cell cancer.

### Claim 15 (depends on 14)

The method of claim 14, wherein the breast cancer is selected from the group consisting of metastatic breast cancer, triple-negative breast cancer, triple-positive breast cancer, HER2-negative breast cancer, HER2-positive breast cancer, estrogen receptor-positive breast cancer, estrogen receptor-negative breast cancer, progesterone receptor-positive breast cancer, progesterone receptor negative breast cancer, ductal carcinoma in situ (OCiS), invasive ductal carcinoma, invasive lobular carcinoma, inflammatory breast cancer, Paget disease of the nipple, phyllodes tumor, and a hormone responsive cancer.

### Claim 16 (depends on 12)

The method of claim 12, wherein the cancer is a CDK4/6-replication dependent cancer.

### Claim 17 (depends on 12)

The method of claim 12, wherein the cancer is a CDK4/6 replication independent cancer.

### Claim 18 (depends on 12)

The method of claim 12, wherein the human is administered the CDK4/6 inhibitor about 30 minutes or less prior to administration of eribulin, or its pharmaceutically acceptable salt.

### Claim 19 (depends on 12)

The method of claim 12, wherein the eribulin is administered on days 1 and 8 of a 21-day chemotherapeutic cycle, and the CDK4/6 inhibitor is administered on days 1 and 8 of a 21-day chemotherapeutic cycle.

### Claim 20 (depends on 12)

The method of claim 12, wherein the eribulin is administered on days 1, 8, and 15 of a 28-day chemotherapeutic cycle, and the CDK4/6 inhibitor is administered on days 1, 8, and 15 of a 28-day chemotherapeutic cycle.

### Claim 21 (depends on 15)

The method of claim 15, further comprising the administration of an anti-hormonal agent, wherein the anti-hormonal agent is selected from the group consisting of a SERM (selective estrogen receptor modulator), a SERD (selective estrogen receptor degrader), a complete estrogen receptor degrader, or another form of partial or complete estrogen antagonist, selective androgen receptor modulator, a selective androgen receptor degrader, a complete androgen receptor degrader, and another form of partial or complete androgen antagonist.

### Claim 22 (depends on 21)

The method of claim 21, wherein the anti-hormonal agent is selected from the group consisting of fulvestrant, tamoxifen, anastrozole, letrozole, exemestane, goserelin, leuprolide, megestrol acetate and toremifene.
